Uveitis News and Research

RSS
Uveitis is an inflammation of the uvea. The uvea is the front part of the eye. It includes the iris, which is the colored part of the eye, and the parts right next to and behind the iris. Uveitis may hurt a lot of parts of the eye. It may last as long as six weeks, or it may last a shorter time.
Immunotherapy medicine found to be effective in treating uveitis

Immunotherapy medicine found to be effective in treating uveitis

Study reveals promising new drug candidate to treat acute renal failure

Study reveals promising new drug candidate to treat acute renal failure

Study: aPKC inhibitors may provide new therapeutic option for blinding eye diseases

Study: aPKC inhibitors may provide new therapeutic option for blinding eye diseases

New safety guideline released for prescribing biological therapies in inflammatory arthritis

New safety guideline released for prescribing biological therapies in inflammatory arthritis

Ocular Syphilis study finds increasing numbers of people at risk for permanent vision damage

Ocular Syphilis study finds increasing numbers of people at risk for permanent vision damage

UK’s leading sight loss charity invites applications from brightest minds in ophthalmic research

UK’s leading sight loss charity invites applications from brightest minds in ophthalmic research

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Fight for Sight partners with CSO to support vital sight-saving Scottish research

Fight for Sight partners with CSO to support vital sight-saving Scottish research

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

FDA approves first stand-alone prosthetic iris in the U.S.

FDA approves first stand-alone prosthetic iris in the U.S.

Ocular oncologists link immunotherapy with potentially vision-robbing side effect

Ocular oncologists link immunotherapy with potentially vision-robbing side effect

Cataract surgery can be safely performed on Ebola survivors with eye disease

Cataract surgery can be safely performed on Ebola survivors with eye disease

Fight for Sight awards new grants for 13 vital eye research projects

Fight for Sight awards new grants for 13 vital eye research projects

FDA grants approval to first treatment for rare blood cancer

FDA grants approval to first treatment for rare blood cancer

New topical treatment to combat skin cancer yields promising results in preliminary study

New topical treatment to combat skin cancer yields promising results in preliminary study

First-ever treatment for Merkel cell carcinoma receives approval in Japan

First-ever treatment for Merkel cell carcinoma receives approval in Japan

Study reveals unique retinal scar in Ebola survivors

Study reveals unique retinal scar in Ebola survivors

Study: Systemic therapy preserves vision of uveitis patients better than intraocular implant

Study: Systemic therapy preserves vision of uveitis patients better than intraocular implant